Hypertension, a leading cause of morbidity and mortality, accounts for 25–49% of all strokes.
Randomized placebo‐controlled trials primarily with diuretics and β‐blockers administered …

We investigated whether protection from coronary heart disease (CHD) and stroke conferred
by angiotensin-converting enzyme inhibitors (ACEIs) and calcium channel blockers (CCBs) …

Objective To review the available literature on the effects of angiotensin-converting enzyme
inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and calcium channel blockers …

From a patient's perspective, stroke is the most devastating form of cardiovascular disease,
representing the number one cause of permanent disability in the United States. Treatment …

In contrast with the expected results, the Captopril Prevention Project study has found that
the relative risk of stroke was greater by 25% in patients treated with ACEI than in patients …

Objectives To compare the effects of angiotensin II receptor blockers and angiotensin-
converting enzyme inhibitors on the risk of myocardial infarction, stroke, cardiovascular …

New strategies to lower the risk of stroke among highrisk persons are being developed.
Therapies such as cholesterol-lowering medications and newer antihypertensive agents …

Reductions in blood pressure (BP) through intervention can significantly reduce the risk of
cardiovascular events in hypertensive patients. However, a number of trials indicate that …

Angiotensin-converting enzyme (ACE) inhibitors continue to find new uses. The Heart
Outcomes Prevention Evaluation study has demonstrated their wide application as a …

Rationale: Patients with a history of cerebrovascular disease have a very high risk of stroke,
and usual levels of both systolic and diastolic blood pressure are directly and continuously …